Epcoritamab-Bysp Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 4 mg/0.8 mL, 48 mg/0.8 mL
Reference Brands: EPKINLY (USA)
Category: Oncology Cancer Care
Epcoritamab (brand name Epkinly) is a bispecific monoclonal antibody that binds to both CD3 on T-cells and CD20 on B-cells, redirecting T-cells to kill malignant B-cells. It is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Administered subcutaneously, Epkinly provides an off-the-shelf immunotherapy alternative to CAR-T treatments. The medicine is jointly developed and marketed by AbbVie and Genmab. Epcoritamab-bysp is available in Injection and strengths such as 4 mg/0.8 mL, 48 mg/0.8 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Epcoritamab-bysp is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Epcoritamab-bysp can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Epcoritamab-bysp is used for the treatment of adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. It works by engaging the patient’s T-cells to target and destroy malignant B-cells, offering a targeted immunotherapy approach for aggressive lymphomas.
Epcoritamab-bysp is made from Epcoritamab-bysp, a bispecific humanized monoclonal antibody that binds both CD3 on T-cells and CD20 on B-cells to promote immune-mediated destruction of cancerous B-cells.
The trade name of Epcoritamab-bysp is Epkinly.
Epcoritamab-bysp (Epkinly) is developed and manufactured by Genmab and AbbVie and marketed under approved regulatory pathways for B-cell lymphoma.
The generic name of Epcoritamab-bysp is Epcoritamab-bysp.
The brand name of Epcoritamab-bysp is Epkinly.
Epcoritamab-bysp is manufactured in the United States and Europe by Genmab and AbbVie under strict GMP conditions for oncology therapeutics.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
